Q4 2024 Abcellera Biologics Inc Earnings Call Transcript
Key Points
- AbCellera Biologics Inc (ABCL) advanced two programs, ABCL 635 and ABCL 575, which are positioned for CTA filing in Q2 2025.
- The company completed its move into a new headquarters and is on track to bring its clinical manufacturing facility online in 2025.
- ABCL closed the year with over $800 million in available liquidity, providing a strong financial position to execute its strategy.
- The company has a robust portfolio of more than 20 pre-clinical programs with potential for high differentiation.
- ABCL has a demonstrated competitive advantage in creating therapeutic antibodies, positioning it well in the market.
- ABCL reported a net loss of approximately $163 million for the year, an increase from the previous year's loss.
- Revenue for the year was almost $29 million, a decrease from approximately $38 million in 2023.
- The company is reducing new discovery partnership activities, which may impact future revenue streams.
- There are risks associated with ABCL 575 being in a competitive space with modest differentiation.
- ABCL's transition from a platform and partnership model to a clinical stage biotech involves significant strategic and operational changes.
Good afternoon and welcome to Apelleus for full year 2024 business update conference call. My name is Tamia, and I will facilitate the audio portion of today's interactive broadcast. If you would like to ask a question, please press 1. Please press 0 should you need assistance during the call. At this time, I would like to turn the call over to Tren Steinmar, Abelera's chief legal and compliance officer. You may proceed.
Thank you. Hello everyone.
Thank you for joining us for Abelera's 2024 full year earnings call. I'm Trent Steinart, of Celera's chief legal and compliance officer. Dr. Carl Hansen, of Celera's President and CEO, and Andrew Booth.
Appelle's CFO are joining me on today's call. During this call, we anticipate making projections and forward-looking statements based on our current expectations and according to the safe harbor provisions of the Private Securities Litigation Reform Act of 1,995. Our actual
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
